Nonviral gene therapy for age-related macular degeneration

Expert Review of Ophthalmology

Volumn 6, Issue 1, 2011, Pages 81-93

  Thumann, Gabriele ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

age related macular degeneration; antiangiogenesis; cell transplantation; gene therapy; microelectroporation; neovascularization; transposons

Indexed keywords

ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BEVACIZUMAB; COPPER; GENE THERAPY AGENT; NANOPARTICLE; PARVOVIRUS VECTOR; PEGAPTANIB; PERIPHERIN 2 PROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; RANIBIZUMAB; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE SUBUNIT 4; RETINAL PIGMENT EPITHELIUM 65 PROTEIN; SLEEPING BEAUTY X100 PROTEIN; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VERTEPORFIN; VIRUS DNA; ZINC;

AUTOTRANSPLANTATION; CATARACT; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; ENDOPHTHALMITIS; GENE DELIVERY SYSTEM; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; INTRAOCULAR HYPERTENSION; LEBER CONGENITAL AMAUROSIS; LEBER HEREDITARY OPTIC NEUROPATHY; NONHUMAN; NONVIRAL GENE THERAPY; PIGMENT EPITHELIUM; RETINA DEGENERATION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETINITIS PIGMENTOSA; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; TRANSPOSON;

EID: 79951902376     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.10.83     Document Type: Review

References (154)

1. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv. Ophthalmol. 44, 1-29 (1999). (Pubitemid 29378350)
2. Klein R, Cruickshanks KJ, Nash SD et al. The prevalence of age-related macular degeneration and associated risk factors. Arch. Ophthalmol. 128, 750-758 (2010).
3. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N. Engl. J. Med. 342, 483-492 (2000). (Pubitemid 30100237)
4. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 48, 257-293 (2003). (Pubitemid 36553096)
5. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS). AREDS report no. 19. Ophthalmology 112, 533-539 (2005). (Pubitemid 41108849)
6. Friedman DS, O'Colmain BJ, Muñoz B et al.; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564-572 (2004). (Pubitemid 38456293)
7. Augood CA, Vingerling JR, de Jong PT et al. Prevalence of age-related maculopathy in older Europeans. The European Eye Study (EurEye). Arch. Ophthalmol. 124, 529-535 (2006).
8. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye 19, 935-944 (2005). (Pubitemid 43114972)
9. Hyman L, Neborsky R. Risk factors for age-related macular degeneration: an update. Curr. Opin. Ophthalmol. 13, 171-175 (2002). (Pubitemid 34518202)
10. San Giovanni JP, Chew EY, Agron E et al. The relationship of dietary w-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration. AREDS report no. 23. Arch. Ophthalmol. 126, 1274-1279 (2008).
11. Mitchel P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy I Australia, the Blue Mountain Eye Study. Ophthalmology 102, 1450-1460 (1995).
12. Feskanich D, Cho E, Schaumberg DA, Colditz GA, Hankinson SE. Menopausal and reproductive factors and risk of age-related macular degeneration. Arch. Ophthalmol. 126, 519-524 (2008). (Pubitemid 351549846)
13. Kawasaki R, Wang JJ, Ji GJ et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 115, 1376-1381 (2008).
14. West SK. Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) project. Arch. Ophthalmol. 126, 241-245 (2008). (Pubitemid 351240854)
15. Klein R, Klein BE, Knudtson MD et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the Multi-ethnic Study of Atherosclerosis. Ophthalmology 113, 373-380 (2006).
16. Hammond CJ, Webster AR, Snieder H, Bird AC, Gilbert CE, Spector TD. Genetic influence on early age-related maculopathy: a twin study. Ophthalmology 109, 730-736 (2002). (Pubitemid 34272274)
17. Klein ML, Mauldin WM, Stoumbos VD. Heredity and age-related macular degeneration. Observations in monozygotic twins. Arch. Ophthalmol. 112, 932-937 (1994). (Pubitemid 24228253)
18. Klein ML, Schultz DW, Edwards A et al. Age-related macular degeneration: clinical features in a large family and linkage to chromosome 1q. Arch. Ophthalmol. 116, 1082-1088 (1998). (Pubitemid 29101833)
19. Katta S, Kaur I, Chakrabarti S. The molecular genetic basis of age-related macular degeneration: an overview. J. Genet. 88, 425-449 (2009).
20. Zarbin MA. Current concepts in the pathogenesis of age related macular degeneration. Arch. Ophthalmol. 122, 598-614 (2004). (Pubitemid 38456297)
21. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and b carotene for age-related cataract and vision loss: AREDS report no. 9. Arch. Ophthalmol. 119, 1439-1452 (2001).
22. Kaiser PK. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch. Clin. Exp. Ophthalmol. 244, 1132-1142 (2006). (Pubitemid 44269592)
23. Hawkins BS, Bressler NM, Miskala PH et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 111, 1967-1980 (2004).
24. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch. Ophthalmol. 110, 1155-1159 (1992).
25. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology 111, 1715-1724 (2004). (Pubitemid 39179688)
26. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch. Clin. Exp. Ophthalmol. 231, 635-641 (1993). (Pubitemid 23342235)
27. Fujii GY, de Juan E Jr, Pieramici DJ et al. Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am. J. Ophthalmol. 134, 69-74 (2002). (Pubitemid 34722712)
28. Aisenbrey S, Bartz-Schmidt KU, Walter P et al. Long-term follow-up of macular translocation with 360° retinotomy for exudative age-related macular degeneration. Arch. Ophthalmol. 125, 1367-1372 (2007). (Pubitemid 47606602)
29. Bereczki A, Bíró Z. Can macular translocation be a satisfactory management of subfoveal choroidal neovascular membrane? Clin. Ophthalmol. 2, 447-450 (2008).
30. Gelisken F, Voelker M, Schwabe R et al. Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch. Clin. Exp. Ophthalmol. 245, 1085-1095 (2007). (Pubitemid 47034332)
31. Ghazi NG, Jabbour NM, De La Cruz ZC et al. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 21, 478-486 (2001). (Pubitemid 32971357)
32. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularisation -verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol. 131, 541-560 (2001).
33. Chen E, Brown DM, Wong TP. Lucentis Using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin. Ophthalmol. 4, 1073-1079 (2010).
34. Bashshur ZF, Schakal AR, El-Mollayess GM et al. Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. Retina DOI: 10.1097/IAE.0b013e3181d5e964 (2010) (Epub ahead of print).
35. Ohno-Matsui K, Hirose A, Yamamoto S et al. Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am. J. Pathol. 160, 711-719 (2002). (Pubitemid 34160349)
36. Ohno-Matsui K. Molecular mechanism for choroidal neovascularization in age-related macular degeneration. Nippon Ganka Gakkai Zasshi 107, 657-673 (2003).
37. Kwak N, Okamoto N, Wood J, Campochiaro P. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 4, 3158-3164 (2004).
38. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816 (2004).
39. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006). (Pubitemid 44511558)
40. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116, 57-65 (2009).
41. Rosenfeld PJ, Brown DM, Heier JS et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006). (Pubitemid 44511557)
42. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J. Ocul. Pharmacol. Ther. 26, 105-110 (2010).
43. Krishnan R, Goverdhan S, Lochhead J. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. Clin. Experiment Ophthalmol. 37, 384-388 (2009).
44. Baeteman C, Hoffart L, Galland F, Ridings B, Conrath J. Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study. J. Fr. Ophtalmol. 32, 309-313 (2009).
45. Emerich DF, Thanos CG. NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr. Opin. Mol. Ther. 10, 506-515 (2008).
46. Garber K. Biotec in a blink. Nat. Biotechnol. 28, 311-315 (2010).
47. Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can. J. Ophthalmol. 40, 313-319 (2009). (Pubitemid 40942258)
48. Bearelly S, Chau FY, Koreishi A, Stinnett SS, Izatt JA, Toth CA. Spectral domain optical coherence tomography imaging of geographic atrophy margins. Ophthalmology 116, 1762-1769 (2009).
49. Anderson WF, Blaese RM, Culver K. The ADA human gene therapy clinical protocol: points to consider response with clinical protocol, July 6, 1990. Hum. Gene Ther. 1, 331-362 (1990).
50. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672 (2000). (Pubitemid 30241569)
51. Hacein-Bey-Abina S, Le Deist F, Carlier F et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185-1193 (2002). (Pubitemid 34984579)
52. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419 (2003). (Pubitemid 37296260)
53. Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158 (2003). (Pubitemid 37272241)
54. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer 3, 477-488 (2003). (Pubitemid 37328836)
55. Stone EM, Fingert JH, Alward WL et al. Identification of a gene that causes primary open angle glaucoma. Science 275, 668-670 (1997). (Pubitemid 27061334)
56. Farrar GJ, Kenna PF, Humphries P. On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J. 21, 857-864 (2002). (Pubitemid 34206159)
57. Ferreira PA. Insights into X-linked retinitis pigmentosa type 3, allied diseases and underlying pathomechanisms. Hum. Mol. Genet. 14(Suppl. 2), R259-R267 (2005). (Pubitemid 41631894)
58. Dinga X, Patela M, Chana CC. Molecular pathology of age-related macular degeneration. Prog. Retin. Eye Res. 28, 1-18 (2009).
59. Molday RS. Photoreceptor membrane proteins, phototransduction, and retinal degenerative diseases. The Friedenwald Lecture. Invest. Ophthalmol. Vis. Sci. 39, 2491-2513 (1998).
60. Acland GM, Aguirre GD, Ray J et al. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92-95 (2001). (Pubitemid 32405824)
61. Maguire AM, Simonelli F, Pierce EA et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248 (2008). (Pubitemid 351724453)
62. Bainbridge JW, Smith J, Barker SS et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239 (2008). (Pubitemid 351724452)
63. Hauswirth WW, Aleman TS, Kaushal S et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a Phase I trial. Hum. Gene Ther. 19, 979-990 (2008).
64. Cideciyan AV, Aleman TS, Boye SL et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl Acad. Sci. USA 105, 15112-15117 (2008).
65. Simonelli F, Maguire AM, Testa F et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18, 643-650 (2010).
66. Campochiaro PA, Nguyen QD, Shah SM et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a Phase I clinical trial. Hum. Gene Ther. 17, 167-176 (2006). (Pubitemid 43262032)
67. Liu MM, Tuo J, Chan CC. Gene therapy for ocular diseases. Br. J. Ophthalmol. DOI: 10.1136/bjo.2009.174912 (2010) (Epub ahead of print).
68. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 132, 1-14 (2008). (Pubitemid 351232078)
69. Hartman ZC, Black EP, Amalfitano A. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology 358, 357-372 (2007). (Pubitemid 46136424)
70. Worgall S, Sondhi D, Hackett NR et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adenoassociated virus expressing CLN2 cDNA. Hum. Gene Ther. 19, 463-474 (2008). (Pubitemid 351748791)
71. Yoshioka Y, Abe T, Wakusawa R et al. Recombinant AAV-transduced iris pigment epithelial cell transplantation may transfer vector to native RPE but suppress systemic dissemination. Invest. Ophthalmol. Vis. Sci. 47, 745-752 (2006). (Pubitemid 46768406)
72. Nair V. Retrovirus-induced oncogenesis and safety of retroviral vectors. Curr. Opin. Mol. Ther. 10, 431-438 (2008).
73. Ginn SL, Liao SH, Dane AP et al. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and g overexpression. Mol. Ther. 18, 965-976 (2010).
74. Liu G, Li D, Pasumarthy MK et al. Nanoparticles of compacted DNA transfect postmitotic cells. J. Biol. Chem. 278, 32578-32586 (2003). (Pubitemid 37055695)
75. Fink TL, Klepcyk PJ, Oette SM et al. Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther. 13, 1048-1051 (2006). (Pubitemid 43905857)
76. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 1, e38 (2006).
77. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, Naash MI. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS ONE 4, e5290 (2009).
78. Ding XQ, Quiambao AB, Fitzgerald JB, Cooper MJ, Conley SM, Naash MI. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS ONE, 4, e7410 (2009).
79. Cai X, Conley SM, Nash Z, Fliesler SJ, Cooper MJ, Naash MI. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J. 24, 1178-1191 (2010).
80. Rebersek M, Faurie C, Kanduser M et al. Electroporator with automatic change of electric field direction improves gene electrotransfer in-vitro. Biomed. Eng. Online 6, 25 (2007).
81. Mutlu GM, Machado-Aranda D, Norton JE et al. Electroporation-mediated gene transfer of the Na+, K+-ATPase rescues endotoxin-induced lung injury. Am. J. Respir. Crit. Care Med. 176, 582-590 (2007). (Pubitemid 47403276)
82. Zeitelhofer M, Vessey JP, Xie Y et al. High-efficiency transfection of mammalian neurons via nucleofection. Nat. Protoc. 2, 1692-1704 (2007).
83. Oshima Y, Sakamoto T, Yamanaka I, Nishi T, Ishibashi T, Inomata H. Targeted gene transfer to corneal endothelium in vivo by electric pulse. Gene Ther. 5, 1347-1354 (1998). (Pubitemid 28482662)
84. Ellouze S, Augustin S, Bouaita A et al. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am. J. Hum. Genet. 83, 373-387 (2008).
85. Man PY, Griffiths PG, Brown DT, Howell N, Turnbull DM, Chinnery PF. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am. J. Hum. Genet. 72, 333-339 (2003). (Pubitemid 36194242)
86. Howell N, Bindoff LA, McCullough DA et al. Leber hereditary optic neuropathy: identification of the same mitochondrial ND1 mutation in six pedigrees. Am. J. Hum. Genet. 49, 939-950 (1991). (Pubitemid 21891740)
87. Wallace DC, Singh G, Lott MT et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 9(242), 1427-1430 (1998).
88. Johns DR, Neufeld MJ, Park RD. An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem. Biophys. Res. Commun. 187, 1551-1557 (1992).
89. Spruijt L, Kolbach DN, de Coo RF et al. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. Am. J. Ophthalmol. 141, 676-682 (2006).
90. Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J. Med. Genet. 46, 145-158 (2009).
91. Butterwick A, Vankov A, Huie P, Freyvert Y, Palanker D. Tissue damage by pulsed electrical stimulation. IEEE Trans. Biomed. Eng. 54, 2261-2267 (2007). (Pubitemid 350157795)
92. Chalberg TW, Vankov A, Molnar FE et al. Gene transfer to rabbit retina with electron avalanche transfection. Invest. Ophthalmol. Vis. Sci. 47, 4083-4090 (2006). (Pubitemid 46044328)
93. Chaum E, Yang H. Transgenic expression of IGF-1 modifies the proliferative potential of human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 43, 3758-3764 (2002). (Pubitemid 35470616)
94. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc. Natl Acad. Sci. USA 101, 16-22 (2004). (Pubitemid 38084195)
95. Johnson CJ, Berglin L, Chrenek MA, Redmond TM, Boatright JH, Nickerson JM. Technical brief: subretinal injection and electroporation into adult mouse eyes. Mol. Vis. 14, 2211-2226 (2008).
96. Lagali PS, Balya D, Awatramani GB et al. Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat. Neurosci. 11, 667-675 (2008). (Pubitemid 351748114)
97. Matsuda T, Cepko CL. Controlled expression of transgenes introduced by in vivo electroporation. Proc. Natl Acad. Sci. USA 104, 1027-1032 (2007). (Pubitemid 46154730)
98. Gouras P, Flood MT, Kjeldbye H. Transplantation of cultured human retinal cells to monkey retina. An. Acad. Bras. Cienc. 56, 431-443 (1984).
99. Gouras P, Flood MT, Kjedbye H, Bilek MK, Eggers H. Transplantation of cultured human retinal epithelium to Bruch's membrane of the owl monkey's eye. Curr. Eye Res. 4, 253-265 (1985). (Pubitemid 15117490)
100. Gouras P, Lopez R, Brittis M, Kjeldbye H. The ultrastructure of transplanted rabbit retinal epithelium. Graefes Arch. Clin. Exp. Ophthalmol. 230, 468-475 (1992).
101. Pinilla I, Cuenca N, Sauve Y, Wang S, Lund RD. Preservation of outer retina and its synaptic connectivity following subretinal injections of human RPE cells in the Royal College of Surgeons rat. Exp. Eye Res. 85, 381-392 (2007). (Pubitemid 47259055)
102. Gias C, Jones M, Keegan D et al. Preservation of visual cortical function following retinal pigment epithelium transplantation in the RCS rat using optical imaging techniques. Eur. J. Neurosci. 25, 1940-1948 (2007). (Pubitemid 46581735)
103. Lund RD, Wang S, Klimanskaya I et al. Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats. Cloning Stem Cells 8, 189-199 (2006). (Pubitemid 44735173)
104. Lawrence JM, Keegan DJ, Muir EM et al. Transplantation of Schwann cell line clones secreting GDNF or BDNF into the retinas of dystrophic Royal College of Surgeons rats. Invest. Ophthalmol. Vis. Sci. 45, 267-274 (2004). (Pubitemid 38055697)
105. Wang S, Lu B, Wood P, Lund RD. Grafting of ARPE-19 and Schwann cells to the subretinal space in RCS rats. Invest. Ophthalmol. Vis. Sci. 46, 2552-2560 (2005). (Pubitemid 43119505)
106. Wang S, Girman S, Lu BR et al. Long-term vision rescue by human neural progenitors in a rat model of photoreceptor degeneration. Invest. Ophthalmol. Vis. Sci. 49, 3201-3206 (2008).
107. Thumann G, Salz AK, Walter P, Johnen S. Preservation of photoreceptors in dystrophic RCS rats following allo-and xenotransplantation of IPE cells. Graefes Arch. Clin. Exp. Ophthalmol. 247, 363-369 (2009).
108. Wang NK, Tosi J, Kasanuki JM et al. Transplantation of reprogrammed embryonic stem cells improves visual function in a mouse model for retinitis pigmentosa. Transplantation 89, 911-919 (2010).
109. Peyman GA, Blinder KJ, Paris CL, Alturki W, Nelson NC Jr, Desai U. A technique for retinal pigment epithelium transplantation for age-related macular degeneration secondary to extensive subfoveal scarring. Ophthalmic Surg. 22, 102-108 (1991).
110. Del Priore LV, Kaplan HJ, Tezel TH, Hayashi N, Berger AS, Green WR. Retinal pigment epithelial cell transplantation after subfoveal membranectomy in age related macular degeneration: clinicopathologic correlation. Am. J. Ophthalmol. 131, 472-480 (2001). (Pubitemid 32273434)
111. Binder S, Stolba U, Krebs I et al. Transplantation of autologous retinal pigment epithelium in eyes with foveal neovascularization resulting from age-related macular degeneration: a pilot study. Am. J. Ophthalmol. 133, 215-224 (2002).
112. Stanga PE, Kychenthal A, Fitzke FW et al. Retinal pigment epithelium transplantation after choroidal neovascular membrane removal in age-related macular degeneration. Ophthalmology 109, 1492-1498 (2002).
113. Van Meurs JC, Van Den Biesen PR. Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: short-term follow-up. Am. J. Ophthalmol. 136, 688-695 (2003). (Pubitemid 37153184)
114. Treumer F, Bunse A, Klatt C, Roider J. Autologous retinal pigment epithelium-choroid sheet transplantation in age related macular degeneration: morphological and functional results. J. Ophthalmol. 91, 349-353 (2007). (Pubitemid 46586533)
115. Falkner-Radler CI, Krebs I, Glittenberg C et al. Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study. Br. J. Ophthalmol. DOI: 10.1136/ bjo.2009.176305 (2010) (Epub ahead of print).
116. Thumann G, Bartz-Schmidt KU, Heimann K, Schraermeyer U. Phagocytosis of rod outer segments by human iris pigment epithelial cells in vitro. Graefes Arch. Clin. Exp. Ophthalmol. 236, 753-757 (1998). (Pubitemid 28458675)
117. Thumann G, Kociok N, Bartz-Schmidt KU, Esser P, Schraermeyer U, Heimann K. Detection of mRNA for proteins involved in retinol metabolism in iris pigment epithelium. Graefes Arch. Clin. Exp. Ophthalmol. 237, 1046-1051 (1999). (Pubitemid 30021297)
118. Freddo T. Intercellular junctions of the iris epithelia in Macaca mulatta. Invest. Ophthalmol. Vis. Sci. 25, 1094-1104 (1984).
119. Hu DN, Ritch R, McCormick SA, Pelton-Henrion K. Isolation and cultivation of human iris pigment epithelium. Invest. Ophthalmol. Vis. Sci. 33, 2443-2453 (1992).
120. Hu DN, McCormick SA, Ritch R. Isolation and culture of iris pigment epithelium from iridectomy specimens of eyes with and without exfoliation syndrome [published correction appears in Arch. Ophthalmol. 115, 650 (1997)]. Arch. Ophthalmol. 115, 89-94 (1997).
121. Thumann G, Bartz-Schmidt KU, El Bakri H et al. Transplantation of autologous iris pigment epithelium to the subretinal space in rabbits. Translocation 68, 195-201 (1999). (Pubitemid 29360276)
122. Crafoord S, Geng L, Seregard S, Algvere PV. Experimental transplantation of autologous iris pigment epithelial cells to the subretinal space. Acta Ophthalmol. Scand. 79, 509-514 (2001). (Pubitemid 32962845)
123. Thumann G, Aisenbrey S, Schraermeyer U et al. Transplantation of autologous iris pigment epithelium after removal of choroidal neovascular membranes. Arch. Ophthalmol. 118, 1350-1355 (2000).
124. Aisenbrey S, Lafaut BA, Szurman P et al. Iris pigment epithelial translocation in the treatment of exudative macular degeneration: a 3-year follow-up. Arch. Ophthalmol. 124, 183-188 (2006). (Pubitemid 43247067)
125. Booij JC, Baas DC, Beisekeeva J, Gorgels TG, Bergen AA. The dynamic nature of Bruch's membrane. Prog. Retin. Eye Res. 29, 1-18 (2010).
126. Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin. Biochem. 39, 267-276 (2006).
127. Gamm DM, Wright LS, Capowski EE et al. Regulation of prenatal human retinal neurosphere growth and cell fate potential by retinal pigment epithelium and Mash1. Stem Cells 26, 3182-3193 (2008).
128. Osborne NN, Chidlow G, Wood JP, Schmidt KG, Casson R, Melena J. Expectations in the treatment of retinal diseases: neuroprotection. Curr. Eye. Res. 22, 321-332 (2001). (Pubitemid 34248291)
129. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 489, 270-276 (2001). (Pubitemid 32126422)
130. Witmer AN, Vrensen GF, van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 22, 1-29 (2003). (Pubitemid 36207453)
131. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Eng. J. Med. 331, 1480-1487 (1994). (Pubitemid 24356306)
132. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab. Rev. 13, 37-50 (1997). (Pubitemid 27213792)
133. Alge CS, Priglinger SG, Neubauer AS et al. Retinal pigment epithelium is protected against apoptosis by aB-crystallin. Invest. Ophthalmol. Vis. Sci. 43, 3575-3582 (2002). (Pubitemid 35334367)
134. Abul-Hassan K, Walmsley R, Boulton M. Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells. Curr. Eye Res. 20, 361-366 (2000). (Pubitemid 30614572)
135. Chiba C, Nakamura K, Unno S, Saito T. Intraocular implantation of DNA-transfected retinal pigment epithelium cells: a new approach for analyzing molecular functions in the newt retinal regeneration. Neurosci. Lett. 368, 171-175 (2004). (Pubitemid 39194866)
136. Bejjani RA, BenEzra D, Cohen H et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 11, 124-132 (2005). (Pubitemid 41358300)
137. Chen J, Xiang N, Xu L, Zeng S. Inhibition of PCNA antisense oligonucleotides mediated by liposome on mRNA expression and proliferation of h-RPE cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. 26, 392-395 (2006).
138. del Pozo-Rodríguez A, Delgado D, Solinís MA, Gascón AR, Pedraz JL. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int. J. Pharm. 360, 177-183 (2008).
139. Fujii Y, Kachi S, Ito A, Kawasumi T, Honda H, Terasaki H. Transfer of gene to human retinal pigment epithelial cells using magnetite cationic liposomes. Br. J. Ophthalmol. 94, 1074-1077 (2010).
140. Abe T, Wakusawa R, Seto H, Asai N, Saito T, Nishida, K. Topical doxycycline can induce expression of BDNF in transduced retinal pigment epithelial cells transplanted into the subretinal space. Invest. Ophthalmol. Vis. Sci. 49, 3631-3639 (2008).
141. Thumann G, Stöcker M, Maltusch C et al. High efficiency non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Ther. 17, 181-189 (2010) .
142. Bateman JR, Wu CT. A simple polymerase chain reaction-based method for the construction of recombinase-mediated cassette exchange donor vectors. Genetics 180, 1763-1766 (2008).
143. Fu Q, Jia S, Sun Z et al. PhiC31 integrase and liver-specific regulatory elements confer high-level, long-term expression of firefly luciferase in mouse liver. Biotechnol. Lett. 31, 1151-1157 (2009).
144. Chalberg TW, Genise HL, Vollrath D, Calos MP. phiC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest. Ophthalmol. Vis. Sci. 46, 2140-2146 (2005).
145. Chalberg TW, Portlock JL, Olivares EC et al. Integration specificity of phage phiC31 integrase in the human genome. J. Mol. Biol. 357, 28-48 (2006). (Pubitemid 43339312)
146. Ehrhardt A, Engler JA, Xu H, Cherry AM, Kay MA. Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum. Gene Ther. 17, 1077-1094 (2006). (Pubitemid 44749710)
147. Liu J, Skjørringe T, Gjetting T, Jensen TG. PhiC31 integrase induces a DNA damage response and chromosomal rearrangements in human adult fibroblasts. BMC Biotechnol. 9, 31 (2009).
148. Vanden Driessche T, Ivics Z, Izsvak Z, Marinee KL, Chuah MKL. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 114, 1461-1468 (2009).
149. Izsvák Z, Hackett PB, Cooper LJ, Ivics Z. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays 32, 756-767 (2010).
150. Liu G, Geurts AM, Yae K et al. Target-site preferences of Sleeping Beauty transposons. J. Mol. Biol. 346, 161-173 (2005). (Pubitemid 40128313)
151. Geurts AM, Hackett CS, Bell JB et al. Structure-based prediction of insertion-site preferences of transposons into chromosomes. Nucleic Acids Res. 34, 2803-2811 (2006). (Pubitemid 43985641)
152. Charbel Issa P, Troeger E, Finger R, Holz FG, Wilke R, Scholl HP. Structure-function correlation of the human central retina. PLoS ONE 5(9) pii e12864 (2010).
153. Liu YY, Chen M, Ishikawa H, Wollstein G, Schuman JS, Rehg JM. Automated macular pathology diagnosis in retinal OCT images using multi-scale spatial pyramid with local binary patterns. Med. Image Comput. Comput. Assist. Interv. 13, 1-9 (2010).
154. Patel N, Ohbayashi M, Nugent AK et al. Circulating anti-retinal antibodies as immune markers in age-related macular degeneration. Immunology 115, 422-430 (2005). (Pubitemid 40896040)